- Home
- SKYE vs USAU Comparison
SKYE vs USAU Comparison
Compare SKYE & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- USAU
- Stock Information
- Founded
- SKYE 2012
- USAU 2014
- Country
- SKYE United States
- USAU United States
- Employees
- SKYE N/A
- USAU N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- USAU Precious Metals
- Sector
- SKYE Health Care
- USAU Basic Materials
- Exchange
- SKYE Nasdaq
- USAU Nasdaq
- Market Cap
- SKYE 121.8M
- USAU 126.8M
- IPO Year
- SKYE N/A
- USAU N/A
- Fundamental
- Price
- SKYE $1.33
- USAU $19.01
- Analyst Decision
- SKYE Strong Buy
- USAU Strong Buy
- Analyst Count
- SKYE 5
- USAU 3
- Target Price
- SKYE $14.75
- USAU $19.00
- AVG Volume (30 Days)
- SKYE 1.8M
- USAU 418.4K
- Earning Date
- SKYE 11-06-2025
- USAU 09-15-2025
- Dividend Yield
- SKYE N/A
- USAU N/A
- EPS Growth
- SKYE N/A
- USAU N/A
- EPS
- SKYE N/A
- USAU N/A
- Revenue
- SKYE N/A
- USAU N/A
- Revenue This Year
- SKYE N/A
- USAU N/A
- Revenue Next Year
- SKYE N/A
- USAU N/A
- P/E Ratio
- SKYE N/A
- USAU N/A
- Revenue Growth
- SKYE N/A
- USAU N/A
- 52 Week Low
- SKYE $1.14
- USAU $5.59
- 52 Week High
- SKYE $5.96
- USAU $19.20
- Technical
- Relative Strength Index (RSI)
- SKYE 27.04
- USAU 65.03
- Support Level
- SKYE $1.50
- USAU $16.67
- Resistance Level
- SKYE $1.76
- USAU $19.05
- Average True Range (ATR)
- SKYE 0.24
- USAU 1.08
- MACD
- SKYE -0.15
- USAU -0.07
- Stochastic Oscillator
- SKYE 0.68
- USAU 94.55
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.